BEN-MAIMON CAROLE — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
BEN-MAIMON CAROLE is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days.
Profile
Carole Ben-Maimon is the President and Chief Executive Officer of Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell-penetrating peptide technology. In this role, she leads the company’s strategic direction and operations, including the development program for its lead asset CTI-1601 aimed at delivering frataxin to the mitochondria in Friedreich’s ataxia patients.
Role
Insider
Notability
40/100
Board memberships
Larimar Therapeutics, Inc.
Awards & honors
Leading a clinical-stage biotech company's strategic direction as CEO
Overseeing development programs for the lead asset CTI-1601
Carole Ben-Maimon is the President and Chief Executive Officer of Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell-penetrating peptide technology. In this role, she leads the company’s strategic direction and operations, including the development program for its lead asset CTI-1601 aimed…
Where can I see all of BEN-MAIMON CAROLE's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
